Overview

EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer

Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, placebo-controlled study for the treatment of head and neck cancer(HNC), to assess the ability of EN3285 to prevent or delay the onset of severe oral mucositis(OM).
Phase:
Phase 3
Details
Lead Sponsor:
Endo Pharmaceuticals